organization · Reporting owner
VEDANTA ASSOCIATES, L.P.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REVIVA PHARMACEUTICALS HOLDINGS, INC.RVPH · Entity 8147 | 10% owner | November 20, 2023 | November 22, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REVIVA PHARMACEUTICALS HOLDINGS, INC.
Report date November 20, 2023 · Filed November 22, 2023
Jointly reported with SAXENA PARAG, VEDANTA PARTNERS, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Pre-Funded WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee Footnote | 585,366 |
Reported balance
After 2023-11-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-11-20 · Other · Acquired 585,366 · Balance 585,366 F1: The reported securities are included within 585,366 units purchased by Vedanta R2 Partners, LP ("Vedanta R2"), an investment vehicle managed by the Reporting Persons, for $5.1249 per unit (each, a "Unit"), with such purchase approved by the board of directors of Reviva Pharmaceuticals Holdings, Inc. (the "Issuer") as exempt from Section 16(b), to the extent applicable, as an acquisition from the Issuer pursuant to Rule 16b-3(d). Each Unit consists of one pre-funded warrant to purchase one share of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock"), and one common stock warrant to purchase one share of Common Stock. F2: The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), no more than 19.99% of the outstanding shares of Common Stock of the Issuer. F3: Held directly by Vedanta R2. Vedanta Associates, L.P. ("Vedanta Associates") is the general partner of Vedanta R2. Vedanta Partners, LLC ("Vedanta Partners") is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners and exercises voting and dispositive power over the securities held by Vedanta Partners. Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein. |
| Common Stock Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2028-11-20 | IndirectSee Footnote | 585,366 |
Reported balance
After 2023-11-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-11-20 · Other · Acquired 585,366 · Balance 585,366 F1: The reported securities are included within 585,366 units purchased by Vedanta R2 Partners, LP ("Vedanta R2"), an investment vehicle managed by the Reporting Persons, for $5.1249 per unit (each, a "Unit"), with such purchase approved by the board of directors of Reviva Pharmaceuticals Holdings, Inc. (the "Issuer") as exempt from Section 16(b), to the extent applicable, as an acquisition from the Issuer pursuant to Rule 16b-3(d). Each Unit consists of one pre-funded warrant to purchase one share of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock"), and one common stock warrant to purchase one share of Common Stock. F4: The common stock warrants expire on November 20, 2028, and are exercisable immediately, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Common Stock of the Issuer. F3: Held directly by Vedanta R2. Vedanta Associates, L.P. ("Vedanta Associates") is the general partner of Vedanta R2. Vedanta Partners, LLC ("Vedanta Partners") is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners and exercises voting and dispositive power over the securities held by Vedanta Partners. Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are included within 585,366 units purchased by Vedanta R2 Partners, LP ("Vedanta R2"), an investment vehicle managed by the Reporting Persons, for $5.1249 per unit (each, a "Unit"), with such purchase approved by the board of directors of Reviva Pharmaceuticals Holdings, Inc. (the "Issuer") as exempt from Section 16(b), to the extent applicable, as an acquisition from the Issuer pursuant to Rule 16b-3(d). Each Unit consists of one pre-funded warrant to purchase one share of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock"), and one common stock warrant to purchase one share of Common Stock.
F2: The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), no more than 19.99% of the outstanding shares of Common Stock of the Issuer.
F3: Held directly by Vedanta R2. Vedanta Associates, L.P. ("Vedanta Associates") is the general partner of Vedanta R2. Vedanta Partners, LLC ("Vedanta Partners") is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners and exercises voting and dispositive power over the securities held by Vedanta Partners. Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein.
F4: The common stock warrants expire on November 20, 2028, and are exercisable immediately, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Common Stock of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 20, 2023 Filed Nov 22, 2023 18:28 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | OtherCommon Stock Warrant (right to buy) · Derivative | 585,366 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001493152-23-042540 · ownership.xml · derivative · entry 2 SAXENA PARAG · CIK 0001015823 · Director · 10% owner VEDANTA PARTNERS, LLC · CIK 0001502216 · 10% owner VEDANTA ASSOCIATES, L.P. · CIK 0001502222 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 585,366 Underlying: Common Stock · 585,366 shares Expires 2028-11-20 F1 · kind: The reported securities are included within 585,366 units purchased by Vedanta R2 Partners, LP ("Vedanta R2"), an investment vehicle managed by the Reporting Persons, for $5.1249 per unit (each, a "Unit"), with such purchase approved by the board of directors of Reviva Pharmaceuticals Holdings, Inc. (the "Issuer") as exempt from Section 16(b), to the extent applicable, as an acquisition from the Issuer pursuant to Rule 16b-3(d). Each Unit consists of one pre-funded warrant to purchase one share of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock"), and one common stock warrant to purchase one share of Common Stock. F1 · price: The reported securities are included within 585,366 units purchased by Vedanta R2 Partners, LP ("Vedanta R2"), an investment vehicle managed by the Reporting Persons, for $5.1249 per unit (each, a "Unit"), with such purchase approved by the board of directors of Reviva Pharmaceuticals Holdings, Inc. (the "Issuer") as exempt from Section 16(b), to the extent applicable, as an acquisition from the Issuer pursuant to Rule 16b-3(d). Each Unit consists of one pre-funded warrant to purchase one share of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock"), and one common stock warrant to purchase one share of Common Stock. F4 · derivative.exercise_date: The common stock warrants expire on November 20, 2028, and are exercisable immediately, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Common Stock of the Issuer. F3 · ownership.nature: Held directly by Vedanta R2. Vedanta Associates, L.P. ("Vedanta Associates") is the general partner of Vedanta R2. Vedanta Partners, LLC ("Vedanta Partners") is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners and exercises voting and dispositive power over the securities held by Vedanta Partners. Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 18:28 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | OtherPre-Funded Warrant · Derivative | 585,366 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001493152-23-042540 · ownership.xml · derivative · entry 1 SAXENA PARAG · CIK 0001015823 · Director · 10% owner VEDANTA PARTNERS, LLC · CIK 0001502216 · 10% owner VEDANTA ASSOCIATES, L.P. · CIK 0001502222 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 585,366 Underlying: Common Stock · 585,366 shares Expires not disclosed F1 · kind: The reported securities are included within 585,366 units purchased by Vedanta R2 Partners, LP ("Vedanta R2"), an investment vehicle managed by the Reporting Persons, for $5.1249 per unit (each, a "Unit"), with such purchase approved by the board of directors of Reviva Pharmaceuticals Holdings, Inc. (the "Issuer") as exempt from Section 16(b), to the extent applicable, as an acquisition from the Issuer pursuant to Rule 16b-3(d). Each Unit consists of one pre-funded warrant to purchase one share of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock"), and one common stock warrant to purchase one share of Common Stock. F1 · price: The reported securities are included within 585,366 units purchased by Vedanta R2 Partners, LP ("Vedanta R2"), an investment vehicle managed by the Reporting Persons, for $5.1249 per unit (each, a "Unit"), with such purchase approved by the board of directors of Reviva Pharmaceuticals Holdings, Inc. (the "Issuer") as exempt from Section 16(b), to the extent applicable, as an acquisition from the Issuer pursuant to Rule 16b-3(d). Each Unit consists of one pre-funded warrant to purchase one share of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock"), and one common stock warrant to purchase one share of Common Stock. F2 · derivative.exercise_date: The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), no more than 19.99% of the outstanding shares of Common Stock of the Issuer. F2 · derivative.expiration_date: The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), no more than 19.99% of the outstanding shares of Common Stock of the Issuer. F3 · ownership.nature: Held directly by Vedanta R2. Vedanta Associates, L.P. ("Vedanta Associates") is the general partner of Vedanta R2. Vedanta Partners, LLC ("Vedanta Partners") is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners and exercises voting and dispositive power over the securities held by Vedanta Partners. Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 16:34 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | PurchaseCommon Stock Warrant (right to buy) · Derivative | 513,834 | $0.00 Strike: $2.40 | $51.38 |
DisclosureSEC source: 0001104659-22-099268 · tm2225524-1_4seq1.xml · derivative · entry 4 VEDANTA PARTNERS, LLC · CIK 0001502216 · 10% owner Vedanta Associates-R, LP · CIK 0001865703 · 10% owner VEDANTA ASSOCIATES, L.P. · CIK 0001502222 · 10% owner BETA OPERATORS FUND, L.P. · CIK 0001614642 · 10% owner SAXENA PARAG · CIK 0001015823 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 513,834 Underlying: Common Stock · 513,834 shares Expires 2027-09-08 F4 · derivative.exercise_date: The common stock warrants expire on September 8, 2027 and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock of the Issuer. F3 · ownership.nature: Held directly by Vedanta Associates-R, L.P. ("Vedanta Associates-R"). Vedanta Partners is the general partner of Vedanta Associates-R, and Parag Saxena is the majority member of Vedanta Partners. Each of Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 16:34 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | PurchaseCommon Stock Warrant (right to buy) · Derivative | 869,565 | $0.00 Strike: $2.40 | $86.96 |
DisclosureSEC source: 0001104659-22-099268 · tm2225524-1_4seq1.xml · derivative · entry 3 VEDANTA PARTNERS, LLC · CIK 0001502216 · 10% owner Vedanta Associates-R, LP · CIK 0001865703 · 10% owner VEDANTA ASSOCIATES, L.P. · CIK 0001502222 · 10% owner BETA OPERATORS FUND, L.P. · CIK 0001614642 · 10% owner SAXENA PARAG · CIK 0001015823 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 869,565 Underlying: Common Stock · 869,565 shares Expires 2027-09-08 F4 · derivative.exercise_date: The common stock warrants expire on September 8, 2027 and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock of the Issuer. F2 · ownership.nature: Held directly by Beta Operators Fund, L.P. ("Beta Operators Fund"). Vedanta Associates, L.P. ("Vedanta Associates") is the general partner of Beta Operators Fund. Vedanta Partners, LLC ("Vedanta Partners") is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners. Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 16:34 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | PurchasePre-Funded Warrant · Derivative | 513,834 | $2.53 Strike: $0.00 | $1,299,948.64 |
DisclosureSEC source: 0001104659-22-099268 · tm2225524-1_4seq1.xml · derivative · entry 2 VEDANTA PARTNERS, LLC · CIK 0001502216 · 10% owner Vedanta Associates-R, LP · CIK 0001865703 · 10% owner VEDANTA ASSOCIATES, L.P. · CIK 0001502222 · 10% owner BETA OPERATORS FUND, L.P. · CIK 0001614642 · 10% owner SAXENA PARAG · CIK 0001015823 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 513,834 Underlying: Common Stock · 513,834 shares Expires not disclosed F1 · derivative.exercise_date: The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock of the Issuer. F1 · derivative.expiration_date: The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock of the Issuer. F3 · ownership.nature: Held directly by Vedanta Associates-R, L.P. ("Vedanta Associates-R"). Vedanta Partners is the general partner of Vedanta Associates-R, and Parag Saxena is the majority member of Vedanta Partners. Each of Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 16:34 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | PurchasePre-Funded Warrant · Derivative | 869,565 | $2.53 Strike: $0.00 | $2,199,912.49 |
DisclosureSEC source: 0001104659-22-099268 · tm2225524-1_4seq1.xml · derivative · entry 1 VEDANTA PARTNERS, LLC · CIK 0001502216 · 10% owner Vedanta Associates-R, LP · CIK 0001865703 · 10% owner VEDANTA ASSOCIATES, L.P. · CIK 0001502222 · 10% owner BETA OPERATORS FUND, L.P. · CIK 0001614642 · 10% owner SAXENA PARAG · CIK 0001015823 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 869,565 Underlying: Common Stock · 869,565 shares Expires not disclosed F1 · derivative.exercise_date: The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock of the Issuer. F1 · derivative.expiration_date: The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock of the Issuer. F2 · ownership.nature: Held directly by Beta Operators Fund, L.P. ("Beta Operators Fund"). Vedanta Associates, L.P. ("Vedanta Associates") is the general partner of Beta Operators Fund. Vedanta Partners, LLC ("Vedanta Partners") is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners. Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 17:31 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | PurchaseWarrants (right to buy) · Derivative | 399,000 | Not disclosed Strike: $4.13 | Not disclosed |
DisclosureSEC source: 0001062993-21-005353 · form4.xml · derivative · entry 6 VEDANTA PARTNERS, LLC · CIK 0001502216 · 10% owner Vedanta Associates-R, LP · CIK 0001865703 · 10% owner VEDANTA ASSOCIATES, L.P. · CIK 0001502222 · 10% owner BETA OPERATORS FUND, L.P. · CIK 0001614642 · 10% owner SAXENA PARAG · CIK 0001015823 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 399,000 Underlying: Common Stock · 299,250 shares Expires 2026-06-01 F1 · price: The securities were purchased as a unit, with each unit consisting of one share of common stock and one warrant exercisable for 0.75 shares of common stock. The purchase price of each unit was $3.75 per share. F3 · ownership.nature: Held directly by Beta Operators Fund, L.P. ("Beta Operators Fund"). Vedanta Associates, L.P. ("Vedanta Associates") is the general partner of Beta Operators Fund. Vedanta Partners is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners. F7 · ownership.nature: Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 17:31 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | PurchaseWarrants (right to buy) · Derivative | 931,000 | Not disclosed Strike: $4.13 | Not disclosed |
DisclosureSEC source: 0001062993-21-005353 · form4.xml · derivative · entry 5 VEDANTA PARTNERS, LLC · CIK 0001502216 · 10% owner Vedanta Associates-R, LP · CIK 0001865703 · 10% owner VEDANTA ASSOCIATES, L.P. · CIK 0001502222 · 10% owner BETA OPERATORS FUND, L.P. · CIK 0001614642 · 10% owner SAXENA PARAG · CIK 0001015823 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 931,000 Underlying: Common Stock · 698,250 shares Expires 2026-06-01 F1 · price: The securities were purchased as a unit, with each unit consisting of one share of common stock and one warrant exercisable for 0.75 shares of common stock. The purchase price of each unit was $3.75 per share. F2 · ownership.nature: Held directly by Vedanta Associates-R, L.P. ("Vedanta Associates-R"). Vedanta Partners, LLC ("Vedanta Partners") is the general partner of Vedanta Associates-R, and Parag Saxena is the majority member of Vedanta Partners. F6 · ownership.nature: Each of Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 17:31 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | PurchaseCommon Stock | 399,000 | $3.75 | $1,496,250.00 |
DisclosureSEC source: 0001062993-21-005353 · form4.xml · nonDerivative · entry 2 VEDANTA PARTNERS, LLC · CIK 0001502216 · 10% owner Vedanta Associates-R, LP · CIK 0001865703 · 10% owner VEDANTA ASSOCIATES, L.P. · CIK 0001502222 · 10% owner BETA OPERATORS FUND, L.P. · CIK 0001614642 · 10% owner SAXENA PARAG · CIK 0001015823 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 399,000 F1 · price: The securities were purchased as a unit, with each unit consisting of one share of common stock and one warrant exercisable for 0.75 shares of common stock. The purchase price of each unit was $3.75 per share. F3 · ownership.nature: Held directly by Beta Operators Fund, L.P. ("Beta Operators Fund"). Vedanta Associates, L.P. ("Vedanta Associates") is the general partner of Beta Operators Fund. Vedanta Partners is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners. F7 · ownership.nature: Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 17:31 UTC | REVIVA PHARMACEUTICALS HOLDINGS, INC. RVPH · Entity 8147 | PurchaseCommon Stock | 931,000 | $3.75 | $3,491,250.00 |
DisclosureSEC source: 0001062993-21-005353 · form4.xml · nonDerivative · entry 1 VEDANTA PARTNERS, LLC · CIK 0001502216 · 10% owner Vedanta Associates-R, LP · CIK 0001865703 · 10% owner VEDANTA ASSOCIATES, L.P. · CIK 0001502222 · 10% owner BETA OPERATORS FUND, L.P. · CIK 0001614642 · 10% owner SAXENA PARAG · CIK 0001015823 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 931,000 F1 · price: The securities were purchased as a unit, with each unit consisting of one share of common stock and one warrant exercisable for 0.75 shares of common stock. The purchase price of each unit was $3.75 per share. F2 · ownership.nature: Held directly by Vedanta Associates-R, L.P. ("Vedanta Associates-R"). Vedanta Partners, LLC ("Vedanta Partners") is the general partner of Vedanta Associates-R, and Parag Saxena is the majority member of Vedanta Partners. F6 · ownership.nature: Each of Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.